Palogic Value Management L.P. Makes New $1.54 Million Investment in Aspen Aerogels, Inc. (NYSE:ASPN)

Palogic Value Management L.P. bought a new stake in shares of Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 130,000 shares of the construction company's stock, valued at approximately $1,544,000. Palogic Value Management L.P. owned 0.16% of Aspen Aerogels as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ASPN. Barclays PLC boosted its stake in Aspen Aerogels by 333.8% during the 3rd quarter. Barclays PLC now owns 92,302 shares of the construction company's stock valued at $2,557,000 after purchasing an additional 71,024 shares during the period. Perigon Wealth Management LLC lifted its stake in shares of Aspen Aerogels by 66.8% in the 4th quarter. Perigon Wealth Management LLC now owns 34,451 shares of the construction company's stock worth $433,000 after acquiring an additional 13,796 shares during the period. Journey Strategic Wealth LLC acquired a new stake in shares of Aspen Aerogels in the 4th quarter worth approximately $178,000. Greenwood Capital Associates LLC lifted its stake in shares of Aspen Aerogels by 5.0% in the 4th quarter. Greenwood Capital Associates LLC now owns 36,938 shares of the construction company's stock worth $439,000 after acquiring an additional 1,749 shares during the period. Finally, Sargent Investment Group LLC lifted its stake in shares of Aspen Aerogels by 14.7% in the 4th quarter. Sargent Investment Group LLC now owns 371,049 shares of the construction company's stock worth $4,723,000 after acquiring an additional 47,680 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Donald R. Young bought 20,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average cost of $5.35 per share, with a total value of $107,000.00. Following the completion of the purchase, the chief executive officer now owns 550,856 shares of the company's stock, valued at $2,947,079.60. This represents a 3.77% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 3.40% of the stock is owned by corporate insiders.

Aspen Aerogels Trading Down 3.1%

Shares of NYSE ASPN traded down $0.19 during mid-day trading on Friday, hitting $5.78. The company's stock had a trading volume of 1,528,874 shares, compared to its average volume of 2,007,638. The stock has a market cap of $474.16 million, a price-to-earnings ratio of 36.10 and a beta of 2.72. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.93 and a quick ratio of 2.48. Aspen Aerogels, Inc. has a one year low of $4.16 and a one year high of $33.15. The company's fifty day simple moving average is $5.74 and its 200-day simple moving average is $9.43.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The construction company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Aspen Aerogels had a net margin of 2.95% and a return on equity of 7.49%. The business had revenue of $78.72 million for the quarter, compared to analyst estimates of $82.75 million. During the same quarter last year, the firm earned ($0.02) EPS. Aspen Aerogels's quarterly revenue was down 16.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Aspen Aerogels, Inc. will post 0.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their price target on shares of Aspen Aerogels from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 14th. Oppenheimer lowered shares of Aspen Aerogels from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 8th. TD Cowen upgraded shares of Aspen Aerogels to a "strong-buy" rating in a report on Tuesday, March 11th. Roth Mkm dropped their target price on shares of Aspen Aerogels from $22.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, February 14th. Finally, Barclays reiterated an "equal weight" rating and issued a $7.00 target price (down from $13.00) on shares of Aspen Aerogels in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $18.44.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.